Creative Medical Technology Holdings Inc (CELZ)

[gint1]

BLah blah blah? PHOENIX, March 11, 2020 /PRNewswire/ -- Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named "IMMCELZ™".

Utilizing the newly discovered properties of regenerative cells to alter immune cells, the Company has found a new method of developing "patient-specific" treatments for diseases in which the immune system pathologically starts to attack healthy tissues in the body, a state termed "autoimmunity".

The autoimmune disease market is estimated to be approximately $38 billion annually1. Common autoimmune diseases include Type 1 diabetes, Rheumatoid arthritis, Psoriasis/Psoriatic arthritis, Multiple sclerosis, Systemic lupus erythematous (lupus), Inflammatory bowel diseases, Myasthenia gravis, Vasculitis, Celiac disease and Hashimoto's Thyroiditis.